Results 201 to 210 of about 297,565 (330)

Cancer risk associated with germline DNA mismatch repair gene mutations.

Human Molecular Genetics, 1997
M. Dunlop, M. Dunlop, S. Farrington, S. Farrington, A. Carothers, A. Wyllie, L. Sharp, J. Burn, Bo Liu, K. Kinzler, B. Vogelstein, B. Vogelstein   +11 more
semanticscholar   +1 more source

Integrating Immune Checkpoint Inhibitors With Total Neoadjuvant Therapy in Proficient Mismatch Repair Rectal Cancer

Annals of Gastroenterological Surgery, EarlyView.
The key to unlocking ICI benefit in pMMR/MSS LARC is to convert “cold” tumors into “hot” ones through lymphocyte‐sparing SCRT and judicious chemotherapy, creating a milieu in which ICIs can act effectively. ABSTRACT The management of locally advanced rectal cancer (LARC) has evolved with the adoption of total neoadjuvant therapy (TNT), integrated ...
Yoshinori Kagawa, Jun Watanabe, Koji Ando, Caleah Kitchens, Aron Bercz, J. Joshua Smith   +5 more
wiley   +1 more source

The DNA mismatch repair protein, MSH6 is a novel regulator of PD-L1 expression. [PDF]

Neoplasia
Brooksbank K, Smith C, Maniati E, Gibson A, Tse WY, Hall AK, Wang J, Sharp TV, Martin SA.   +8 more
europepmc   +1 more source

Oligonucleotide-directed mutagenesis screen to identify pathogenic Lynch syndrome-associated MSH2 DNA mismatch repair gene variants [PDF]

, 2016
Hellen Houlleberghs, Marleen Dekker, Hildo Lantermans, Roos Kleinendorst, Hendrikus J. Dubbink, Robert M.W. Hofstra, Senno Verhoef, Hein te Riele   +7 more
openalex   +1 more source

Engineered RNA Devices for In Vivo Targeted Therapeutics via Advanced Delivery Systems

Aggregate, EarlyView.
Schematic illustration of engineered RNA devices for in vivo targeted therapeutics via advanced delivery systems. ABSTRACT Engineered RNA devices can identify disease‐specific markers and precisely regulate gene expression, which is of great significance to the development of precision medicine.
Wei Luo, Xia Liu, Ying Han, Yijing Duan, Chuao Yu, Na Kong, Tian Xie   +6 more
wiley   +1 more source

Somatic Mutations in DNA Mismatch Repair Genes, Mutation Rate and Neoantigen Load in Acute Lymphoblastic Leukemia. [PDF]

Pharmaceuticals (Basel)
Mendiola-Soto DK, Gómez-Romero L, Núñez-Enríquez JC, Flores-Lujano J, Jiménez-Hernández E, Medina-Sansón A, Bekker-Méndez VC, Mata-Rocha M, Pérez-Saldívar ML, Duarte-Rodríguez DA, Torres-Nava JR, Peñaloza-González JG, Flores-Villegas LV, Amador-Sánchez R, Velázquez-Aviña MM, Martín-Trejo JA, Merino-Pasaye LE, Solís-Labastida KA, Espinosa-Elizondo RM, Pérez-Amado CJ, May-Hau DI, Sepúlveda-Robles OA, Rosas-Vargas H, Mejía-Aranguré JM, Jiménez-Morales S.   +24 more
europepmc   +1 more source

Establishment and molecular profiling of a PDX model of a metachronous brain tumor in a patient with constitutional mismatch repair deficiency with biallelic MSH6 variant

Animal Models and Experimental Medicine, EarlyView.
A 6½‐year‐old girl was diagnosed with a medulloblastoma, SHH activated, subtype 3 and TP53 mutant (somatic). After surgery and chemotherapy, she was monitored with quarterly magnetic resonance imaging (MRI) scans and remained free of disease for almost 4 years.
Daniel Antunes Moreno, Bruna Minniti Mançano, Mirella Baroni, Eric Allison Philot, Felipe Antonio de Oliveira Garcia, Murilo Bonatelli, Flávia Escremim de Paula, Iara Viana Vidigal Santana, Gustavo Ramos Teixeira, Mauricio Yamanari, Luciane Sussuchi da Silva, André Escremim de Paula, Augusto Perazzolo Antoniazzi, Adrian Willig, Xiaobin Xing, Zhenyu Xu, Lucas Lourenço, Carlos Almeida Junior, Silvia Aparecida Teixeira, Rui Manuel Reis   +19 more
wiley   +1 more source

RNA/DNA-binding protein TDP43 regulates DNA mismatch repair genes with implications for genome stability. [PDF]

Nucleic Acids Res
Provasek VE, Bacolla A, Rangaswamy S, Kodavati M, Mitra J, Yusuf IO, Malojirao VH, Vasquez V, Britz GW, Li GM, Xu Z, Mitra S, Garruto RM, Tainer JA, Hegde ML.   +14 more
europepmc   +1 more source

Analysis of tumor PD-L1 expression and biomarkers in relation to clinical activity in patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) + ipilimumab (IPI): CheckMate 142

, 2017
Thierry André, Michael J. Overman, Sara Lonardi, Massimo Aglietta, Ray McDermott, Ka Yeung Mark Wong, Michael A. Morse, Alain Hendlisz, Rebecca A. Moss, Jean-Marie Ledeine, Hao Tang, Z. Alexander Cao, Scott Kopetz   +12 more
openalex   +2 more sources

Generating golden Syrian hamsters with conditional alleles via zygote microinjection of CRISPR/Cas9

Animal Models and Experimental Medicine, EarlyView.
We established the first conditional knockout (cKO) model in the golden Syrian hamster by CRISPR/Cas9‐mediated genome editing. Cas9 protein, two sgRNAs, and a donor plasmid carrying loxP‐flanked exon 2 of the ApoF gene were microinjected into one‐cell embryos. The floxed allele was efficiently generated (up to 27%) and transmitted through the germline.
Wei Chen, Xu Zhang, Rui Fan, Xia Li, Feifei Guan, Gefan Wan, Weining Kong, Xiaolong Qi, Shuo Pan, Sijing Shi, Yuanlong Su, Shan Gao, Wei Huang, Xunde Xian, Jiangning Liu, Yuhui Wang, Yuanwu Ma   +16 more
wiley   +1 more source